Linked Life Data

18245546

Source:http://linkedlifedata.com/resource/pubmed/id/18245546

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18245546rdf:typepubmed:Citationlld:pubmed
pubmed-article:18245546lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18245546lifeskim:mentionsumls-concept:C0877373lld:lifeskim
pubmed-article:18245546lifeskim:mentionsumls-concept:C0055966lld:lifeskim
pubmed-article:18245546lifeskim:mentionsumls-concept:C0246415lld:lifeskim
pubmed-article:18245546lifeskim:mentionsumls-concept:C0920321lld:lifeskim
pubmed-article:18245546lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:18245546lifeskim:mentionsumls-concept:C1328699lld:lifeskim
pubmed-article:18245546lifeskim:mentionsumls-concept:C0599533lld:lifeskim
pubmed-article:18245546pubmed:issue3lld:pubmed
pubmed-article:18245546pubmed:dateCreated2008-2-4lld:pubmed
pubmed-article:18245546pubmed:abstractTextClusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment resistance. OGX-011 is a 2'-methoxyethyl-modified phosphorothioate antisense oligonucleotide that is complementary to clusterin mRNA, has a prolonged tissue half life, enhances drug efficacy in xenograft models, and reduces clusterin expression in humans with a biologically effective dose of 640 mg. The objective of this study was to determine a recommended phase II dose of OGX-011 in combination with docetaxel.lld:pubmed
pubmed-article:18245546pubmed:languageenglld:pubmed
pubmed-article:18245546pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18245546pubmed:citationSubsetIMlld:pubmed
pubmed-article:18245546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18245546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18245546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18245546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18245546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18245546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18245546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18245546pubmed:statusMEDLINElld:pubmed
pubmed-article:18245546pubmed:monthFeblld:pubmed
pubmed-article:18245546pubmed:issn1078-0432lld:pubmed
pubmed-article:18245546pubmed:authorpubmed-author:EisenhauerEli...lld:pubmed
pubmed-article:18245546pubmed:authorpubmed-author:GleaveMartinMlld:pubmed
pubmed-article:18245546pubmed:authorpubmed-author:HirteHalHlld:pubmed
pubmed-article:18245546pubmed:authorpubmed-author:TuDongshengDlld:pubmed
pubmed-article:18245546pubmed:authorpubmed-author:SiuLillian...lld:pubmed
pubmed-article:18245546pubmed:authorpubmed-author:WalshWendyWlld:pubmed
pubmed-article:18245546pubmed:authorpubmed-author:HotteSebastie...lld:pubmed
pubmed-article:18245546pubmed:authorpubmed-author:ChiKim NKNlld:pubmed
pubmed-article:18245546pubmed:authorpubmed-author:PowersJeanJlld:pubmed
pubmed-article:18245546pubmed:authorpubmed-author:GunsEmmaElld:pubmed
pubmed-article:18245546pubmed:authorpubmed-author:KnoxJenniferJlld:pubmed
pubmed-article:18245546pubmed:authorpubmed-author:Kollmansberge...lld:pubmed
pubmed-article:18245546pubmed:issnTypePrintlld:pubmed
pubmed-article:18245546pubmed:day1lld:pubmed
pubmed-article:18245546pubmed:volume14lld:pubmed
pubmed-article:18245546pubmed:ownerNLMlld:pubmed
pubmed-article:18245546pubmed:authorsCompleteYlld:pubmed
pubmed-article:18245546pubmed:pagination833-9lld:pubmed
pubmed-article:18245546pubmed:meshHeadingpubmed-meshheading:18245546...lld:pubmed
pubmed-article:18245546pubmed:meshHeadingpubmed-meshheading:18245546...lld:pubmed
pubmed-article:18245546pubmed:meshHeadingpubmed-meshheading:18245546...lld:pubmed
pubmed-article:18245546pubmed:meshHeadingpubmed-meshheading:18245546...lld:pubmed
pubmed-article:18245546pubmed:meshHeadingpubmed-meshheading:18245546...lld:pubmed
pubmed-article:18245546pubmed:meshHeadingpubmed-meshheading:18245546...lld:pubmed
pubmed-article:18245546pubmed:meshHeadingpubmed-meshheading:18245546...lld:pubmed
pubmed-article:18245546pubmed:meshHeadingpubmed-meshheading:18245546...lld:pubmed
pubmed-article:18245546pubmed:meshHeadingpubmed-meshheading:18245546...lld:pubmed
pubmed-article:18245546pubmed:year2008lld:pubmed
pubmed-article:18245546pubmed:articleTitleA phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.lld:pubmed
pubmed-article:18245546pubmed:affiliationBritish Columbia Cancer Agency, Vancouver Centre, Vancouver, British Columbia, Canada. kchi@bccancer.bc.calld:pubmed
pubmed-article:18245546pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18245546pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:18245546pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18245546lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18245546lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18245546lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18245546lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18245546lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18245546lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18245546lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18245546lld:pubmed